en weer een advies verlaging
UBS Group downgraded shares of Celyad Oncology (NASDAQ:CYAD) from a neutral rating to a sell rating in a report issued on Wednesday morning, The Fly reports.
Other equities research analysts have also recently issued research reports about the stock. HC Wainwright lowered their price objective on shares of Celyad Oncology from $15.00 to $13.00 and set a buy rating for the company in a research report on Friday, December 10th. Zacks Investment Research raised shares of Celyad Oncology from a hold rating to a buy rating and set a $4.75 price objective on the stock in a research note on Wednesday, December 15th.
Shares of CYAD stock opened at $4.00 on Wednesday. Celyad Oncology has a 52-week low of $3.53 and a 52-week high of $9.26. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.42 and a current ratio of 0.97. The firm has a fifty day moving average of $4.25 and a 200-day moving average of $4.44.
A hedge fund recently bought a new stake in Celyad Oncology stock. OLD Mission Capital LLC acquired a new position in shares of Celyad Oncology SA (NASDAQ:CYAD) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,323 shares of the company’s stock, valued at approximately $60,000. OLD Mission Capital LLC owned 0.07% of Celyad Oncology as of its most recent SEC filing. 1.83% of the stock is owned by institutional investors and hedge funds.
About Celyad Oncology